About this Journal Submit a Manuscript Table of Contents
International Journal of Pediatrics
Volume 2014 (2014), Article ID 981465, 4 pages
http://dx.doi.org/10.1155/2014/981465
Clinical Study

IVIG Effects on Erythrocyte Sedimentation Rate in Children

Pediatric Department, Bouali Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil 56157, Iran

Received 27 August 2013; Revised 9 November 2013; Accepted 11 November 2013; Published 29 January 2014

Academic Editor: Joel R. Rosh

Copyright © 2014 Farhad Salehzadeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. L. Brigden, “Clinical utility of the erythrocyte sedimentation rate,” The American Family Physician, vol. 60, no. 5, pp. 1443–1450, 1999. View at Scopus
  2. E. Susana and T. B. Booker, “Erythrocyte sedimentation rate from folklore to facts,” The American Journal of Medicine, vol. 78, no. 6, part 1, pp. 1001–1009, 1985.
  3. C. L. Altergott, M. A. Letouneau, M. K. O'Connor, C. Vance, L. S. Chan, and N. Schonfeld-Warden, “Early determination of ESR: how accurate is it?” Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 5, pp. 487–489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Hameed and S. Waqas, “Physiological basis and clinical utility of erythrocyte sedimentation rate,” Pakistan Journal of Medical Sciences, vol. 22, no. 2, pp. 214–218, 2006. View at Scopus
  5. M. Plebani and E. Piva, “Erythrocyte sedimentation rate: use of fresh blood for quality control,” The American Journal of Clinical Pathology, vol. 117, no. 4, pp. 621–626, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Hooper, “Intravenous immunoglobulins: evolution of commercial IVIG preparations,” Immunology and Allergy Clinics of North America, vol. 28, no. 4, pp. 765–778, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Ballow, “Mechanisms of action of intravenous immune serum globulin therapy,” Pediatric Infectious Disease Journal, vol. 13, no. 9, pp. 806–811, 1994. View at Scopus
  8. S. C. Jordan, M. Toyoda, and A. A. Vo, “Intravenous immunoglobulin a natural regulator of immunity and inflammation,” Transplantation, vol. 88, no. 1, pp. 1–6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Hamrock, “Adverse events associated with intravenous immunoglobulin therapy,” International Immunopharmacology, vol. 6, no. 4, pp. 535–542, 2006.
  10. K.-Y. Lee, H.-S. Lee, J.-H. Hong, J.-W. Han, J.-S. Lee, and K.-T. Whang, “High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki disease,” Journal of Tropical Pediatrics, vol. 51, no. 2, pp. 98–101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Karlikaya, G. Yuksel, B. Yildirim, C. Orken, and H. Tireli, “Intravenous immunglobulin treatment: the effect on different hematological and biochemical parameters,” Journal of Neurological Sciences, vol. 24, no. 2, pp. 104–108, 2007.
  12. V. Ignjatovic, C. Lai, R. Summerhayes et al., “Age-related differences in plasma proteins: How plasma proteins change from neonates to adults,” PLoS ONE, vol. 6, no. 2, Article ID e17213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. V. Kaveri, “Intravenous immunoglobulin: exploiting the potential of natural antibodies,” Autoimmunity Reviews, vol. 11, no. 11, pp. 792–794, 2012. View at Publisher · View at Google Scholar · View at Scopus